Neuromodulation Device Market Innovations and Trends

Drug delivery via the inhalation route is currently in demand for treatment of various diseases including asthma and chronic obstructive pulmonary disorders.

Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.

Drug innovation and the product pipeline in the cardiometabolic space is lagging due to the inherent time and cost of evidence generation needed for regulatory evaluation and approvals.

Since the first immune checkpoint blocker ipilimumab was approved by the US FDA in 2011, more drug companies have sought to develop their own immune therapy drugs.